# Avacta plc Deliver strong set of results (Interview)

- Link: https://www.directorstalkinterviews.com/avacta-plc-deliver-strong-set-of-results-interview/412803867
- Published: 2020-01-24T08:03:34+00:00
- Author: Giles Arbor

**[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l)
plc** ([LON: AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l))
CEO Alastair Smith joins DirectorsTalk to discuss its trading update for the 17 
month period ended 31 December 2019. Alastair explains why its a 17 month reporting
period, what drove the strong growth, why the cash position is better than expected
and what investors should be looking out for over the year.

Avacta is developing novel cancer immunotherapies combining its two proprietary 
platforms – Affimer® biotherapeutics and pre|CISION™ tumour targeted chemotherapy.
With this approach, the Company aims to address the lack of a durable response to
current immunotherapies experienced by most patients. The Company’s therapeutics
development activities are based in Cambridge, UK.

The Company benefits from near-term revenues generated from Affimer reagents for
diagnostics, bioprocessing and research, through a separate business unit based 
in Wetherby, UK.

The Affimer platform is an alternative to antibodies derived from a small human 
protein. Despite their shortcomings, antibodies currently dominate markets worth
in excess of $100bn. Affimer technology has been designed to address many of these
negative performance issues, principally: the time taken, and the reliance on an
animal’s immune response, to generate new antibodies; poor specificity in many cases;
large size and cost.

Avacta’s pre|CISION platform, activates chemotherapy only in the tumour, thereby
limiting systemic exposure and damage to healthy tissues, and thus improving the
overall safety and therapeutic potential of these powerful anti-cancer treatments.

By combining these two platforms the Company is building a wholly owned pipeline
of novel cancer therapies with the aim of creating effective treatments for all 
cancer patients including those who do not respond to existing immunotherapies. 
Avacta expects to take its first drug, a pre|CISION targeted form of the standard-
of-care Doxorubicin, into the clinic in the middle of 2020.

Avacta has established drug development partnerships with pharma and biotech, including
with Moderna Therapeutics Inc., a collaboration with LG Chem to develop treatments
for autoimmune and inflammatory diseases worth up to $310m, a partnership with ADC
Therapeutics to develop Affimer drug conjugates and a joint venture in South Korea
with Daewoong Pharmaceuticals to develop the next generation of stem cell therapies
that incorporate Affimer immuno-modulators. Avacta actively seeks to license its
proprietary platforms in a range of therapeutic areas.

The Avacta diagnostics business unit works with partners world-wide to develop Affimers
for evaluation by those third parties with the objective of establishing royalty
bearing license deals. The Company is also developing a small in-house pipeline 
of Affimer-based diagnostic assays for licensing.

Share on:
